Literature DB >> 29019081

Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.

Yu Xiong1,2, Manon Mouginot1, Loic Reppel1,3, Chongsheng Qian1, Jean-Francois Stoltz1,3, Danièle Bensoussan1,3, Véronique Decot4,5.   

Abstract

The ability of natural killer (NK) cells to kill tumor cells without antigen recognition makes them appealing as an adoptive immunotherapy. However, NK cells are not routinely used in the context of leukemic relapse after hematopoietic stem cell transplantation. Patients who experience relapse can be treated with donor lymphocyte infusions (DLI) based on small-cell fractions frozen at the time of transplantation. Since peripheral blood stem cells (PBSCs) are increasingly used as a stem cell source and as a source of cells for DLI, we aimed to evaluate the impact of G-SCF mobilization on NK cell phenotype, subset repartition, and functionality. Immunomagnetically isolated NK cells from healthy donor blood, donor PBSCs, and patient PBSCs were expanded for 14 days with IL-15. The expansion capacity, phenotype, and functions (cytokine secretion and cytotoxicity) of NK cell subsets based on CD56 and CD16 expression were then evaluated. Mobilized sources showed a significant decrease of CD56brightCD16+ NK cells (28 versus 74%), whereas a significant increase (64 versus 15%) of CD56brightCD16- NK cells was observed in comparison with peripheral blood. Patient-mobilized NK cells showed a significantly decreased cytotoxicity, and antibody-dependent cell cytototoxicity (ADCC) was also observed to a lesser extent in NK cells from healthy donor PBSC. G-CSF-mobilized NK cell TNF-α and IFN-γ secretion was impaired at day 0 compared to healthy donors but was progressively restored after culture. In conclusion, expansion of NK cells from G-CSF-mobilized sources may progressively improve their functionality.

Entities:  

Keywords:  Cytotoxicity; Expansion; Granulocyte colony-stimulating factor; Immunotherapy; Interleukin 15; Natural killer cells

Mesh:

Substances:

Year:  2017        PMID: 29019081     DOI: 10.1007/s12026-017-8955-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  26 in total

1.  Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.

Authors:  Véronique Decot; Laure Voillard; Véronique Latger-Cannard; Lamia Aissi-Rothé; Pascale Perrier; Jean Francois Stoltz; Daniele Bensoussan
Journal:  Exp Hematol       Date:  2010-02-19       Impact factor: 3.084

Review 2.  Human CD56bright NK Cells: An Update.

Authors:  Tatiana Michel; Aurélie Poli; Angelica Cuapio; Benjamin Briquemont; Gilles Iserentant; Markus Ollert; Jacques Zimmer
Journal:  J Immunol       Date:  2016-04-01       Impact factor: 5.422

3.  G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.

Authors:  Y-C Su; S-C Li; C-K Hsu; C-C Yu; T-J Lin; C-Y Lee; H-F Liao
Journal:  Bone Marrow Transplant       Date:  2011-02-28       Impact factor: 5.483

4.  A common pathway mediated through Toll-like receptors leads to T- and natural killer-cell immunosuppression.

Authors:  Ilan Vaknin; Liora Blinder; Lynn Wang; Roi Gazit; Elena Shapira; Olga Genina; Mark Pines; Eli Pikarsky; Michal Baniyash
Journal:  Blood       Date:  2007-11-08       Impact factor: 22.113

5.  NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.

Authors:  Loredana Ruggeri; Antonella Mancusi; Emanuela Burchielli; Marusca Capanni; Alessandra Carotti; Teresa Aloisi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood Cells Mol Dis       Date:  2007-10-26       Impact factor: 3.039

6.  G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo.

Authors:  Han C Toh; Li Sun; Yatanar Soe; Yonghui Wu; Yee P Phoon; Whay K Chia; Jeanie Wu; Kee Y Wong; Patrick Tan
Journal:  Clin Immunol       Date:  2009-04-02       Impact factor: 3.969

7.  Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation.

Authors:  Meng Lv; Xiao-Su Zhao; Yue Hu; Ying-Jun Chang; Xiang-Yu Zhao; Yuan Kong; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Am J Hematol       Date:  2015-01       Impact factor: 10.047

8.  Genetic variant of the G-CSF receptor gene is associated with lower mobilization potential and slower recovery of granulocytes after transplantation of autologous peripheral blood progenitor cells.

Authors:  Katarzyna Bogunia-Kubik; Anna Gieryng; Katarzyna Gebura; Andrzej Lange
Journal:  Cytokine       Date:  2012-07-15       Impact factor: 3.861

9.  Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients.

Authors:  Piotr Trzonkowski; Jan Maciej Zaucha; Jolanta Mysliwska; Joanna Balon; Ewa Szmit; Kazimierz Halaburda; Maria Bieniaszewska; Monika Mlotkowska; Andrzej Hellmann; Andrzej Mysliwski
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

10.  Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab.

Authors:  Sebastian P Haen; Benjamin J Schmiedel; Kathrin Rothfelder; Bastian J Schmied; Truong-Minh Dang; Nora Mirza; Robert Möhle; Lothar Kanz; Wichard Vogel; Helmut R Salih
Journal:  Oncotarget       Date:  2016-03-15
View more
  1 in total

1.  Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.

Authors:  Lei Gao; Yanqi Zhang; Sanbin Wang; Peiyan Kong; Yi Su; Jiong Hu; Ming Jiang; Hai Bai; Tao Lang; Jishi Wang; Li Liu; Tonghua Yang; Xiaobing Huang; Fang Liu; Shifeng Lou; Yao Liu; Cheng Zhang; Hong Liu; Li Gao; Jia Liu; Lidan Zhu; Qin Wen; Ting Chen; Ping Wang; Jun Rao; Min Mao; Cunbang Wang; Xianlin Duan; Le Luo; Xiangui Peng; Kaniel Cassady; Jiang F Zhong; Xi Zhang
Journal:  J Clin Oncol       Date:  2020-10-27       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.